

**IN THE CLAIMS**

This listing of the claims replaces all prior versions of the claims in the application.

1-73. (canceled)

74. (currently amended): ~~The method of claim 31, wherein said anti-HER2 antibody is Hereceptin® recombinant humanized 4D5 monoclonal antibody~~ A method of treating a subject for a breast cancer characterized by overexpression of the HER2 receptor protein, said method comprising concurrent therapy with the recombinant, humanized anti-HER2 antibody Trastuzumab and the recombinant des-alanyl-1, serine-125 human interleukin-2 molecule Aldesleukin, wherein said concurrent therapy comprises administering to said subject at least one therapeutically effective dose of said Aldesleukin in combination with a dosing regimen for said Trastuzumab, wherein said dosing regimen for said Trastuzumab comprises administering to said subject at least one therapeutically effective dose of said Trastuzumab, wherein said therapeutically effective dose of said Trastuzumab is in the range from about 1.0 mg/kg to about 10.0 mg/kg and wherein said therapeutically effective dose of said Aldesleukin is in the range from about 0.5 MIU/m<sup>2</sup> to about 4.0 MIU/m<sup>2</sup>.

75-78. (canceled)

79. (currently amended): ~~The method of claim 63, wherein said anti-HER2 antibody is Hereceptin® recombinant humanized 4D5 monoclonal antibody~~ A method of treating a subject for a breast cancer characterized by overexpression of the HER2 receptor protein, said method comprising concurrent therapy with the recombinant, humanized anti-HER2 antibody Trastuzumab and an IL-2 polypeptide, wherein said concurrent therapy comprises administering to said subject at least one therapeutically effective dose of said IL-2 polypeptide in combination with a dosing regimen for said Trastuzumab, wherein said dosing regimen for said humanized anti-HER2 antibody comprises administering to said subject at least one therapeutically effective dose of said Trastuzumab, wherein said therapeutically effective dose of said Trastuzumab is in

the range from about 1.0 mg/kg to about 10.0 mg/kg and wherein said therapeutically effective dose of said IL-2 polypeptide is in the range from about 0.5 MIU/m<sup>2</sup> to about 4.0 MIU/m<sup>2</sup>.

80. (new): The method of claim 74, wherein said therapeutically effective dose of said Aldesleukin is administered as a pharmaceutical composition selected from the group consisting of a monomeric Aldesleukin pharmaceutical composition, a multimeric Aldesleukin pharmaceutical composition, a lyophilized Aldesleukin pharmaceutical composition, and a spray-dried Aldesleukin pharmaceutical composition.

81. (new): The method of claim 74, wherein said therapeutically effective dose of said Trastuzumab is in the range from about 2.0 mg/kg to about 9.0 mg/kg and wherein said therapeutically effective dose of said Aldesleukin is in the range from about 0.6 MIU/m<sup>2</sup> to about 3.0 MIU/m<sup>2</sup>.

82. (new): The method of claim 81, wherein said therapeutically effective dose of said Trastuzumab is in the range from about 3.0 mg/kg to about 8.0 mg/kg and wherein said therapeutically effective dose of said Aldesleukin is in the range from about 0.8 MIU/m<sup>2</sup> to about 1.5 MIU/m<sup>2</sup>.

83. (new): The method of claim 82, wherein said therapeutically effective dose of said Trastuzumab is about 4.0 mg/kg and wherein said therapeutically effective dose of said Aldesleukin is about 1.0 MIU/m<sup>2</sup>.

84. (new): The method of claim 79, wherein said therapeutically effective dose of said IL-2 is administered as a pharmaceutical composition selected from the group consisting of a monomeric IL-2 pharmaceutical composition, a multimeric IL-2 pharmaceutical composition, a lyophilized IL-2 pharmaceutical composition, and a spray-dried IL-2 pharmaceutical composition.

85. (new): The method of claim 79, wherein said therapeutically effective dose of said anti-HER2 antibody is in the range from about 2.0 mg/kg to about 9.0 mg/kg and wherein said therapeutically effective dose of said IL-2 is in the range from about 0.6 MIU/m<sup>2</sup> to about 3.0 MIU/m<sup>2</sup>.

86. (new): The method of claim 85, wherein said therapeutically effective dose of said anti-HER2 antibody is in the range from about 3.0 mg/kg to about 8.0 mg/kg and wherein said therapeutically effective dose of said IL-2 is in the range from about 0.8 MIU/m<sup>2</sup> to about 1.5 MIU/m<sup>2</sup>.

87. (new): The method of claim 86, wherein said therapeutically effective dose of said anti-HER2 antibody is about 4.0 mg/kg and wherein said therapeutically effective dose of said IL-2 is about 1.0 MIU/m<sup>2</sup>.